107 results
Pulmonary complications of targeted therapy
-Immune checkpoint inhibitors (e.g. pembrolizumab)
-Pneumonitis is uncommon (~5% of patients) but can
pembrolizumab) -Pneumonitis ... well as radiation pneumonitis ... during therapy. -1/ ... common presenting symptom ... clinical diagnosis pneumonitis
Nodular pattern
1. Hypersensitivity pneumonitis: ill defined centrilobular nodules.
2. Miliary TB: random nodules
3. Sarcoidosis: nodules with perilymphatic
Nodular pattern 1. ... Hypersensitivity pneumonitis ... : ill defined centrilobular ... Hypersensitivity pneumonitis
On the left some diseases with a nodular pattern.
1. Hypersensitivity pneumonitis: ill defined centrilobular nodules.
2. Miliary
nodular pattern. 1. ... Hypersensitivity pneumonitis ... : ill defined centrilobular ... Hypersensitivity pneumonitis ... bronchiolitis: ill
Heme Synthesis Pathway
Enzymes
1. ALA Synthase
2. ALA Dehydratase
3. Porphobilinogen deaminase
4. UP Ill Synthase
5. UP Ill Decarboxylase
6. Coproporphyrinogen
Pathway Enzymes 1. ... UP Ill Synthase ... UP Ill Decarboxylase ... Synthesis #Pathway #pathophysiology
Hypothermia in Sepsis - Pathophysiology
 • 20% of septic pts → HYPOTHERMIA
 • Increased mortality 62%
Hypothermia in Sepsis - Pathophysiology ... insufficiency MECHANISMS: 1. ... cytokines ↓TNF-α, ↓IL ... -6, ↓IL-1 3. ... Hypothermia #sepsis #pathophysiology
Anaphylaxis: Signs and Symptoms
Anaphylaxis: when any egg of three conditions is met:
1. Acute onset of skin/mucosal
Anaphylaxis: Signs and Symptoms ... conditions is met: 1. ... involvement with 2 1 ... Signs / Symptoms ... #Anaphylaxis #pathophysiology
Fig. 1 Pathophysiology of septic myocardial dysfunction. IL interleukin, iNOS induced nitric oxide synthase, PMN polymorphonuclear
Fig. 1 Pathophysiology ... IL interleukin, ... necrosis factor #Pathophysiology
Osteoporosis: Pathogenesis and risk factors

 • Age > 30 (post-peak bone mass)
 • Post-menopausal women ->
- Celiac - IBD ... #Osteoporosis #pathophysiology ... #signs #symptoms
Lyme Disease: Early and Late Clinical manifestations
Stage 1. Localized
 • EM appears 7-14 days at the
manifestations Stage 1. ... abnormalities are rare and mild ... joints (knees), 1- ... Washington University ID ... diagnosis #signs #symptoms
Immune Reactions and Immunosuppressant Drugs

Glucocorticoids - Inhibition of cytokine synthesis, e.g., IL-1, IL-2
Muromonab-CD3 - Monoclonal antibody
Calcineurin
., IL-1, IL-2 Muromonab-CD3 ... cytokine synthesis - IL ... Basiliximab - IL ... Suppression of IL ... #Pharmacology #Pathophysiology